LIVE POLIO IRUS VACCINES

Index
633
Vaccine, Attenuated, Trivalent-continued
United States and Latin America, 330-340
virological and serological findings, 207, 240-265,
270-276
Vaccine, Killed (Salk), 342, 363, 477, 561
advantages and disadvantages, comparison with
live, 3, 414, 487, 519
and antibody levels, 156, 164, 347, 439
and attack rate, Mauritius, 475-476
and socio-economic class, 446, 598
and spread study, 154, 169, 597
by age groups, 215, 439, 457
conversion rates, 211, 512, 532
correct pathological reaction in human, 578
effectiveness, 375, 514, 576, 595
extensive program impossible, 582
history, 145-146, 158, 210, 229, 322, 357, 373, 438,
440, 446, 459, 462, 592
incomplete and polio cases, 454
inferiority of Type 1 and 3 antigens, 336, 440
insufficient antigen produces sensitizing agent, 374
intradermal route, 199, 507, 532
large-scale use, Union of South Africa, 474-475
need for quantitative studies, 374
Netherlands, 143
no interference with live, 337
number doses, 203, 509
of expectant mothers, 208
polio incidence increased despite, 330, 373-375, 459,
482
prepared in Japan, 191
statistics, 419, 579
sutpplemented with live Type 1, reason, 596
two injections before trial, 522, 535
unsatisfactory protection, 6, 435
virus excretion not affected, 171, 202, 205, 603
Vacuolating agent
antigenic relationships, 83
biological properties, 84
cytopathic effect, 83
effect masked by polio infection, 88
Hilleman results confirmed, 87
identified only in tissue cultures of Cercopithecus
aethiops, 601
in live vaccines, 88
in vaccinated children, 132
new simian virus of Rhesus and Cynuomolgus monkey-kidney
origin, 79
origins of 8 strains, 80
physical properties, 84
strains appear to comprise a single immunologic
group, 83
test stools of persons receiving, in vaccine, 88
Valenciano, L., paper 68-78
Van Gieson staining technique, 69
Van Rooyen, C. E., 203, 375-376, 432
Vargas, María José Ramírez, see Ramírez Vargas,
María José
Vargas-Méndez, Oscar, paper 561-568; 118, 174, 184,
532, 574-575, 591, 593, 600
Variety Children's Research Foundation
antibody determinations, 439
Vasiliev, K. G., paper 482-501
Vasilieva, K. A., paper 413-428
Vehicle
cherry-flavored syrup, 114, 342, 387
dragée-candy, 241, 264, 414, 419, 585
gelatin capsules, 342, 357
milk, 278, 294
pasty candy, 414
syrup, 199, 507
water, 535
Veld rodent (Mystromys albicaudatus)
attempt to attenuate Lansing strain by passage in,
474
Verlinde, J. D., paper 134-142; 67, 133, 143, 174, 429
Vervets, see also Green monkeys
eight simian agents described, 86
paralysis after IC inoculation, 474
vacuolating agent study, 87-88
Viet Nam
3% of monkeys have foamy agent, 88
vaccine supplied by USSR, 419, 582
Vignec, Dr. -, 101
Viral agents
continued investigation into meaning, 8
in currently available vaccines, 7
neighboring communities different, 151
quantitative aspects, 28
Viremia, 357-364
blood specimens, 358
blood tests in children to determine appearance of,
47
demonstration, technique, 352
feeding and, 371
monkey neurovirulence after IM inoculation, 23
neurovirulent vaccines and, 50
occurrence significance, 372
pregnancy, 372
reactions, 364
related to antibody titer for all three types, 363
spillover versus multiplication, 100
standardization, 600
summary of laboratory results, 361, 363
to Type 1 and Type 3 readily produced, 458
Type 2, no difference in neurovirulence of vaccine
and isolate, 373
vaccination not contraindicated, 368
Virological findings
absence of types in stools, 271, 487
Virulence
in monkeys, technique, 536
not increased in virus from contacts, 323
rapid changes during laboratory propagation, 127
sudden increase at 180th passage, 474
Virus, see also particular kinds of virus, e.g.: Simian
virus; Coxsackie
experimental mixture, 205
virus-acute antibody complexes, 228
"wild virus" infection control, 308
Virus excretion
duration, 207, 231, 313, 538
in children fed CHAT and Fox (table), 527
relation to antibody response, 205, 238, 602